On this page

Tecentriq Hybreza

atezolizumab and hyaluronidase-tqjs

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Tecentriq Hybreza

Proper name

atezolizumab and hyaluronidase-tqjs

Licence type

351(a)

BLA number

761347

Applicant

Genentech, Inc.

Center

CDER

Presentations

First licensure

—

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
1,875MG/15ML; 30,000UNITS/15ML (125MG/2,000UNITS/ML)	Injection	Subcutaneous	Single-Dose Vial	Rx	September 12, 2024

Purple Book	FDA	Licence type, presentations, reference product, exclusivity